At Zetagen, we do what we do because we commit to Walk with You.

Our first “Compassionate Use” patient was Colleen Connor. This is her story:

As we walked with Colleen, we journeyed with her through her highs and lows. We held her hand and rejoiced with her as she experienced reduced pain and her spinal lesions were no longer active.

Before ZetaMet™ Colleen was taking 250mg of morphine per day (equivalent to 59, 5mg Percocet per day).

2 of the spinal lesions were mature and had been previously treated with radiation but returned, and 5 new sacral spinal lesions had materialized.

The median survival rate for Metastatic Breast Cancer to Bone is 9 months
(4.8 months if fractured).

After 60 Days on ZetaMet™

Colleen's pain was reduced 4x fold.

All 7 spinal lesions were treated with ZetaMet, all remained inactive for 36 months and the sacral lesions completely resolved (never came back).

On Tuesday, September 10th, 2024, Colleen lost her battle with cancer due to disease progression in soft tissue organs.

With ZetaMet™, Colleen survived 36 months, and experienced a greater quality of life in the midst of her battle.

Two years following her initial treatment, Colleen said to us:

“Thank you for giving me more time!”

We have commemorated our lab as the Colleen Connor Cancer Research Lab in honor of her life and our friendship with her.

Just like we walked with Colleen, we are here to Walk with You.

We have commemorated our facility as the Colleen Connor Cancer Research Lab in honor of her life and our friendship with her.

Just like we walked with Colleen, we are here to Walk with You.

"True compassion means not only feeling another's pain but also being moved to help relieve it."

- Daniel Goleman Psychologist, Author and Science Journalist

Learn More about our clinical trials

LEARN MORE